Vaporizable Formulation of 5-MeO-DMT and THCV as Prophylactic or Therapeutic Agent for Treatment-Resistant Depression (TRD) and Anxiety Disorders

A novel treatment approach for treatment-resistant depression and chronic anxiety combines the rapid neuroplastic effects of the psychedelic 5-MeO-DMT with the anxiolytic properties of the cannabinoid THCV, delivered via a precision vaporization device. The THCV acts as a 'cushion' to prevent the panic and acute activity increase often triggered by high-potency psychedelics, while allowing the tryptamine to promote synaptic growth and reset the Default Mode Network. This synergistic combination aims to provide more effective and tolerable relief than existing antidepressants, which require weeks to work and do not address synaptic atrophy.

Study at a glance

Abstract

The global burden of mental health conditions, including Treatment-Resistant Depression (TRD) and chronic anxiety, has increased. Existing treatments like SSRIs, SNRIs, and TCAs often require weeks for efficacy and do not address synaptic atrophy or the rapid "reset" of the Default Mode Network (DMN) required for immediate relief. While 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) shows rapid antidepressant effects, its intensity often triggers panic responses. In contrast, Tetrahydrocannabivarin (THCV) has demonstrated anxiolytic properties without significant psychoactivity at lower doses. The present work describes a novel approach via a precision vaporization device that co-administers a specific ratio of 5-MeO-DMT and THCV. This is designed to allow the neuroplastic benefits of the tryptamine to occur within a "cushion" of cannabinoid-mediated anxiolysis, preventing the acute activity increase and panic often observed with high-potency psychedelics. This synergistic combination offers potential for a more effective and tolerable treatment for TRD and anxiety disorders, leveraging the distinct properties of 5-MeO-DMT and THCV.